Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Christopher Medlock Doesn’t Think Heron Therapeutics Inc (HRTX)’s Gains This Year Will Stop At A Mere 220%

Page 1 of 2

Christopher Medlock JamesPartner Fund Management recently initiated a position in Heron Therapeutics Inc (NASDAQ:HRTX), together with its affiliated funds, according to a 13G form filed with the Securities and Exchange Commission. The holding comprises over 2.01 million shares valued at $65.30 million based on the June 10 closing price, and represents about  5.7% of the $1.14 billion biotechnology company’s outstanding shares.


Founded in 2004, Partner Fund Management currently has about $5.44 billion worth of regulatory assets under its management. The San Francisco-based investment firm combines fundamental analysis with a bottom-up approach to make its investment choices, and complements its in-house research with external research. At the end of March the market value of the fund’s public equity portfolio stood at $3.63 billion and the healthcare sector represented about 55% of these holdings.

Christopher Medlock James
Christopher Medlock James
Partner Fund Management

Most investors can’t outperform the stock market by individually picking stocks because stock returns aren’t evenly distributed. A randomly picked stock has only a 35% to 45% chance (depending on the investment horizon) to outperform the market. There are a few exceptions, one of which is when it comes to purchases made by corporate insiders. Academic research has shown that certain insider purchases historically outperformed the market by an average of seven percentage points per year. This effect is more pronounced in small-cap stocks. Another exception is the small-cap stock picks of hedge funds. Our research has shown that the 15 most popular small-cap stocks among hedge funds outperformed the market by nearly a percentage point per month between 1999 and 2012. We have been forward testing the performance of these stock picks since the end of August 2012 and they have returned more than 135% over the ensuing 34 months, outperforming the S&P 500 Index by nearly 80 percentage points (read the details here). The trick is focusing only on the best small-cap stock picks of funds, not their large-cap stock picks which are extensively covered by analysts and followed by almost everybody.

Heron Therapeutics Inc (NASDAQ:HRTX) is focused on improving the therapeutic profile of injectable pharmaceuticals. Its main product candidate, SUSTOL is being developed to prevent chemotherapy-induced nausea and vomiting (CINV). The company announced successful results for its Phase 3 study of SUSTOL at the end of May, and plans to re-submit its New Drug Application to the FDA. The drug met its primary endpoint of a statistically significant proportion of patients achieving a Complete Response as compared to the Comparator Group. The Complete Response was defined as no vomiting or rescue medications during a 24 to 120-hour period after administration of highly emetogenic chemeotherapy agents, which are responsible for causing vomiting. Moreover, Heron Therapeutics Inc (NASDAQ:HRTX) has also recently initiated a mid-stage study of HTX-011, which helps with the prevention of post-operative pain.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!